Coherex Wave Crest: New device for atrial appendage closure

Appendage closure devices have emerged as an alternative to anticoagulation in fibrillated patients with a contraindication for it. The study included 63 patients with paroxysmal, persistent or permanent FA coupled with a CHADS score >1 and eligible to interrupt anticoagulation. The primary endpoint was atrial appendage occlusion evaluated by ultrasound between 45 and 180 days after. After 45 days, 97% of patients had the right atrial appendage occluded and none had adverse events. 

Conclusion: This new device seems easy to use and safe, with a 97% success rate in the implant and 97% occlusion of the atrial appendage at 45 days.

Richard Heuser
2013-05-23

Original title: Left atrial appendage closure with the Coherex Wave Crest left atrial appendage closure device. 

More articles by this author

Coronary obstruction registry after TAVI

There is little information in the literature about the obstruction of the coronary ostia after percutaneous aortic valve implantation. 81 TAVI sites and programs...

Clinical results of TAVI in Asia

Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia...

RIPCORD study: FFR changes clinical consideration of chest pain

The objective of this study was to evaluate whether routine use of FFR in all the coronary arteries could change the strategy in stable...

PATA – STEMI: thromboaspiration correlates with a lower index of microcirculatory resistance

Routine manual vacuum in patients with acute coronary syndrome and ST-segment elevation improves myocardial perfusion according to non-invasive parameters. Invasive assessment of microcirculation has...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...